Free Trial
LON:YGEN

Yourgene Health (YGEN) Share Price, News & Analysis

Yourgene Health logo

About Yourgene Health Stock (LON:YGEN)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
13.15 million shs
Average Volume
21.98 million shs
Market Capitalization
£16.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. It develops in vitro diagnostic products, such as IONA Test, a non-invasive pre-natal test (NIPT) for Down's syndrome, Edwards' syndrome, and Patau's Syndrome in pregnant women; Cystic Fibrosis Screening tests; Rapid Aneuploidy Analysis, a confirmatory diagnostic test carried out after amniocentesi; and Recurrent Pregnancy Loss, a PCR assay for the routine diagnosis of the six most common chromosomes related to pregnancy loss, as well as DPYD genotyping products. The company also offers Ranger, a technology platform for sample size selection and enrichment; Elucigene DPYD assay, a PCR test to predict a patient's response to a chemotherapy treatment; and Clarigene SARS-CoV-2 CE-IVD, a PCR assay used for routine COVID-19 testing. In addition, it provides genomic services; sample preparation and analysis tools; and bioinformatics and software products, as well as extraction for DNA, RNA/miRNA, and nucleons; quantification; genotyping; gene expression; methylation; and microarray services for clinical research organizations. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. Yourgene Health Plc was incorporated in 2000 and is headquartered in Manchester, the United Kingdom. As of September 8, 2023, Yourgene Health Plc operates as a subsidiary of Novacyt UK Holdings Limited.

Receive YGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yourgene Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

YGEN Stock News Headlines

Yourgene Health Launches Insight DPYD Assay
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
See More Headlines

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
LON:YGEN
CIK
N/A
Fax
N/A
Employees
253
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
9
Net Income
-£8.17 million
Net Margins
-27.55%
Pretax Margin
N/A
Return on Equity
-27.06%
Return on Assets
-6.71%

Debt

Debt-to-Equity Ratio
68.93
Current Ratio
1.37
Quick Ratio
1.17

Sales & Book Value

Annual Sales
£29.67 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
1.53
Book Value
GBX 4 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
3,190,000,000
Free Float
N/A
Market Cap
£16.43 million
Optionable
Not Optionable
Beta
0.86
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (LON:YGEN) was last updated on 9/8/2023 by MarketBeat.com Staff.
From Our Partners